Ovid Therapeutics to Present at Upcoming September Investor Conferences

Rhea-AI Summary

Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on rare epilepsies and brain conditions, has announced its participation in two major investor conferences this September. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th at 3:30 p.m. ET. Additionally, Ovid will engage in a fireside chat at the Cantor Global Healthcare Conference on September 17th at 1:55 p.m. ET.

Both events will be webcast live and can be accessed through the Events & Presentations section of Ovid's investor website. Archived replays will be available on the company's website following the live presentations, providing investors and interested parties with opportunities to stay informed about Ovid's latest developments and strategic outlook.

News Market Reaction

%

1 alert

% News Effect

On the day this news was published, OVID declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in two upcoming investor conferences in September:

• H.C. Wainwright 26th Annual Global Investment Conference – Ovid will present on September 10th at 3:30 p.m. ET.
• Cantor Global Healthcare Conference – Ovid will participate in a fireside chat on Tuesday, September 17th at 1:55 p.m. ET.

Live webcasts of the fireside chat and presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.

About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company that is dedicated to improving the lives of people affected by rare epilepsies and brain conditions with seizure symptoms. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. Ovid is developing: OV888/GV101 capsule, a potent and highly selective ROCK2 inhibitor, for the potential treatment of cerebral cavernous malformations and other rare central nervous system diseases; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.

Investor Relations:
Garret Bonney
617-735-6093
gbonney@ovidrx.com

FAQ

When is Ovid Therapeutics presenting at the H.C. Wainwright Global Investment Conference?

Ovid Therapeutics (OVID) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th at 3:30 p.m. ET.

What is the date and time of Ovid Therapeutics' fireside chat at the Cantor Global Healthcare Conference?

Ovid Therapeutics (OVID) will participate in a fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 17th at 1:55 p.m. ET.

How can investors access Ovid Therapeutics' presentations at the September conferences?

Investors can access live webcasts of Ovid Therapeutics' (OVID) presentations through the Events & Presentations section of the company's website at investors.ovidrx.com. Archived replays will also be available after the live events.

What is the focus of Ovid Therapeutics as a biopharmaceutical company?

Ovid Therapeutics (OVID) is a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions.